We consider this approval an important advance in the treatment of head and neck cancer because it has been shown to help some patients live longer. Patients need as many effective treatment options as possible.
Today's approval is a major step forward in making breakthrough treatments available for patients with rare and difficult to treat forms of cancer.
This approval is a welcome addition to the available defenses against the flu. This new use offers the medical community another option to prevent and control influenza A and B.